Euglycemic diabetic ketoacidosis (EDKA) is an exceptional diabetic complication associated with various risk factors to a degree fasting, surgery, gestation, and now the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors. EDKA is generally related to an inequality between insulin and counter-regulatory hormones, accompanying an elevated glucagon/insulin ratio. EDKA can bring about serious snags, including significant aridity, if not acknowledged early and treated appropriately accompanying fluids, dextrose, and insulin. In the context of sane blood glucose levels, it is from an increased anion gap metabolic upset stomach with ketonemia/ketonuria. Pregnancy, extended abstaining, and bariatric surgery are low risk factors for the development concerning this illness. As a sporadic cause of euDKA, sodium-hydrogen cotransporter-2 (SGLT-2) inhibitors have been found. Euglycemic diabetic ketoacidosis (DKA, EDKA) is a clinical syndrome happening both in type 1 (T1DM) and type 2 (T2DM) diabetes mellitus characterized by euglycemia (level of glucose in blood less than 250 mg/dL) in the appearance of severe metabolic acidosis (arterial pH inferior 7.3, serum bicarbonate inferior 18 mEq/L) and ketonemia. A recent literature review erect only 77 case reports of euDKA secondary to SGLT-inhibitors published in the healing literature until 02 August, 2020.Here, we present the case of a 43-year-old man the one was taking empagliflozin, an SGLT-2 inhibitor. The patient was raise to have euDKA, which was likely an antagonistic effect of his medication.
Author(s) Details:
Sukhjinder Chauhan,
Sunrise
Health Consortium GME, Las Vegas, Nevada, USA.
Andre
Manov,
Sunrise
Health Consortium GME, Las Vegas, Nevada, USA.
Pinak Shah,
Sunrise Health Consortium GME, Las Vegas, Nevada, USA.
Please see the link here: https://stm.bookpi.org/NRAMMS-V7/article/view/12155
No comments:
Post a Comment